


# Scientific Program

3<sup>rd</sup> World Congress on

## Hepatitis and Liver Diseases

October 10-12, 2016 Dubai, UAE



### Supporting Sponsors

**Hepatoma Research**  
(Hepatoma Res)

**JCMT**  
Journal of Cancer  
Metastasis  
and Treatment

**TECHNOLOGY**  
NETWORKS

Hosting Organization: Conference Series LLC

2360 Corporate Circle., Suite 400 Henderson, NV 89074-7722, USA, Ph: +1-888-843-8169, Fax: +1-650-618-1417, Toll free: +1-800-216-6499

Heathrow Stockley Park Lakeside House, 1 Furzeground Way, Heathrow, UB11 1BD, UK, Tel: +1-800-216-6499

Email: [hepatitis@conferenceseries.net](mailto:hepatitis@conferenceseries.net), [hepatitis@gastroconferences.com](mailto:hepatitis@gastroconferences.com)

Day 1 October 10, 2016

08:00-09:00 Registrations

conference**series**.com

Salon II III

09:00-09:30

## Opening Ceremony

### Keynote Forum

09:30-09:35 Introduction

**Title: Possible Role of Estrogen Receptors in Gender Susceptibility in the Development of Chronic Infections and Liver Cancers**

09:35-10:15

**Anil Kaul**, Oklahoma State University, USA

10:15-10:55

**Title: Nucleic Acid Polymers: broad spectrum antiviral agents and their development as the backbone of new antiviral therapies for the treatment of chronic HBV and HDV infection**

**Andrew Vaillant**, Replicor Inc, Canada

Panel Discussion

Group Photo: 10:55-11:00

Networking & Refreshment Break 11:00-11:20 @ Foyer

11:20-12:00 **Workshop on Increase of specific social score EPICES before and after direct antiviral agent treatment in HCV patients in France: 2 years experience**

**Bouchkira Hakim & Andre-Jean Remy**, Perpignan Hospital, France

Session:

Hepatitis Care and Cure | Hepatitis B | Hepatitis C | Hepatitis Vaccination | Liver Diseases

Session Chair: **Andrew Vaillant**, Replicor Inc, Canada

Session Co-chair: **Asad I Dajani**, ADSC, United Arab Emirates

Session Introduction

12:00-12:30 **Title: Hepatitis C Virus (HCV) genotype 1b as a risk factor for hepatocellular carcinoma development in chronic HCV positive patients in Southern Italy**

**Arnolfo Petruzzello**, IRCCS, Italy

12:30-13:00

**Title: Direct acting antivirals; are they truly the last nails in the coffin of HCV ??**

**Fatma Abdelaziz Amer**, Zagazig University, Egypt

Lunch Break 13:00-13:45 @ Market Place

13:45-14:15 **Title: Nucleic Acid Polymers: Application in the treatment of chronic HBV and HDV infection and potentiating the effects of immunotherapy**

**Andrew Vaillant**, Replicor Inc, Canada

14:15-14:45 **Title: Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis**

**Ligita Jancoriene**, Vilnius University Hospital, Lithuania

14:45-15:15 **Title: Current therapeutic approaches to NAFLD treatment**

**Asad I Dajani**, Arab Doctors Specialist, UAE

15:15-15:45 **Title: Hepatitis B revaccination to students whom firstly demonstrated anti-HBs negative or titer <10 mIU/ml**

**Prapan Jutavijittum**, Chiang Mai University, Thailand

Networking & Refreshment Break 15:45-16:05 @ Foyer

16:05-16:35 **Title: Therapeutic trial to assess the efficacy and safety of folic acid and/or vitamin B complex on hepatitis C infected patients treated with pegylated interferon and ribavirin**

**Nermeen Nabil Ashoush**, The British University in Egypt, Egypt

16:35-17:05 **Title: Potent and broad spectrum medicinal drugs against all genotypes of hepatitis C virus (HCV)**

**Mahmoud Fahmi Elsebai**, Mansoura University, Egypt

17:05-17:35 **Title: Circulating microRNAs as non-invasive biomarkers for the detection of different stages of liver fibrosis in Egyptian HCV patients**

**Eman El-Ahwany**, Theodor Bilharz Research Institute, Egypt

Panel Discussion

Day 2 October 11, 2016

Salon II III

### Keynote Forum

09:00-09:05 Introduction

**Title: Hepatitis C virus (HCV) infection: A global epidemiology up-date of the circulation of HCV genotypes**

09:05-09:45

**Arnolfo Petruzzello**, National Cancer Institute, Italy

09:45-10:25 **Title: Sepsis in Cirrhotics**  
Alaaeldin Ibrahim, ACDS, UAE

Panel Discussion

Networking and Refreshments 10:25-10:45 @ Foyer

10:45-11:45 **Workshop on Economic Evaluation in Health and Medicine**  
Nermeen Nabil Ashoush, The British University in Egypt, Egypt

Sessions:

**Genetic and Metabolic Liver Diseases | Liver Disease Diagnosis | Liver Cancer | Non-Viral Hepatitis | Drug discovery for treatment of Hepatitis**

**Session Chair: Anil Kaul, Oklahoma State University, USA**

**Session Co-chair: Andre-Jean Remy, Perpignan Hospital, France**

Session Introduction

11:45-12:15 **Title: Hepatitis mobile team: A new concept for benefit toward drugs users and precarious people with hepatitis C in France**

**Andre-Jean Remy, Perpignan Hospital, France**

12:15-12:45 **Title: Treating patients with hepatitis C genotype 1 using Viekira Pak™ in the real world: An Australian nursing perspective**

**Vince Fragomeli, Nepean Hospital, Australia**

12:45-13:15 **Title: New Insights into the Roadmap of Pathogenesis of Liver Fibrosis**

**Eman El-Ahwany, Theodor Bilharz Research Institute, Egypt**

Lunch Break 13:15-14:00 @ Market Place

Poster Presentations 14:00-14:45 @ Foyer

HP-001 **Title: CT arterial enhancement fraction (AEF) for hepatocellular carcinoma (HCC) screening in patients with end-stage liver cirrhosis**

**Andreas Christe, University Hospital of Bern, Switzerland**

HP-002 **Title: The association of genetic variation near interleukin 28B and UCKL-1 protein expression in liver tissue of patients with hepatitis C induced hepatocellular carcinoma**

**Arida Buivydiene, Vilnius University, Lithuania**

HP-003 **Title: Impact of different polymorphisms of IL 10 in prevalence of liver fibrosis and progression in hepatitis C patients**

**Ali Rahman, University Hospital of Bern, Switzerland**

HP-004 **Title: PHF20-mediated SREBP regulation is required for the enhancement of lipogenesis and hepatic steatosis in PHF20 transgenic mice**

**Jisoo Park, Chungnam National University, South Korea**

HP-005 **Title: Suggested function of *Tabebuia avellanedae* extract on alcoholic fatty liver disease**

**Hyunji Lee, Chungnam National University, South Korea**

HP-006 **Title: Matrine as a new treatment for hepatosteatosis by suppressing ER stress-associated de novo lipogenesis**

**Ali Mahzari, RMIT University, Australia**

HP-007 **Title: Beliefs and knowledge about cancer among educated women in Riyadh, Saudi Arabia**

**Shayma Asrar, Al-Maarefa Colleges, KSA**

14:45-15:15 **Title: 40 years observation in Liver diseases in the Middle East**

**Makki H Fayadh, ACDS, UAE**

15:15-15:45 **Title: Genetics in hepatitis B**

**Osama Hasan Othman, University of Kirkuk, Iraq**

15:45-16:15 **Title: Matrine eliminates hepatosteatosis and glucose intolerance in high fructose-fed mice by suppressing ER stress associated de novo lipogenesis in the liver**

**Ali Mahzari, RMIT University, Australia**

Networking & Refreshment Break 16:15-16:35 @ Foyer

16:35-17:05 **Title: We can beat the frightening ghost, HCC**  
**Medhat El-Hosary, Kafr elsheikh Liver Research Center, Egypt**

17:05-17:35 **Title: Hepatitis B Antigen Quantification**  
**Salem Awadh, Advanced Center for Day Care Surgery LLC, UAE**

Panel Discussion

Awards Ceremony

Day 3 October 12, 2016

Extended Networking Session & Lunch 12:00-13:30 @ Market Place

Closing Ceremony